^
BIOMARKER:

EGFR T790M

i
Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Entrez ID:
EGFR T790M
LUAD
brigatinib
Sensitive: C3 – Early Trials
Cancer Med - 2 weeks
EGFR T790M
NSCLC
osimertinib
Sensitive: A1 - Approval
EGFR T790M
NSCLC
lazertinib
Sensitive: A1 - Approval
EGFR T790M
NSCLC
almonertinib
Sensitive: A1 - Approval
EGFR T790M
Lung Non-Squamous Non-Small Cell Cancer
osimertinib
Sensitive: A2 - Guideline
EGFR T790M
LUAD
erlotinib
Sensitive: B - Late Trials
EGFR T790M
NSCLC
afatinib
Sensitive: B - Late Trials
EGFR T790M
NSCLC
erlotinib + ramucirumab
Sensitive: B - Late Trials
EGFR T790M
LUAD
gefitinib
Sensitive: B - Late Trials
EGFR T790M
NSCLC
bevacizumab
Sensitive: B - Late Trials
EGFR T790M
LUAD
osimertinib
Resistant: C1 - Off-label
EGFR T790M
NSCLC
bevacizumab + osimertinib
Sensitive: C2 – Inclusion Criteria
EGFR T790M
NSCLC
rociletinib
Sensitive: C2 – Inclusion Criteria
EGFR T790M
NSCLC
ASP8273
Sensitive: C2 – Inclusion Criteria
EGFR T790M
NSCLC
ASK120067
Sensitive: C2 – Inclusion Criteria
EGFR T790M
NSCLC
osimertinib + ramucirumab
Sensitive: C2 – Inclusion Criteria
EGFR T790M
NSCLC
olmutinib
Sensitive: C2 – Inclusion Criteria
EGFR T790M
NSCLC
osimertinib + ABT 263
Sensitive: C2 – Inclusion Criteria
EGFR T790M
NSCLC
gefitinib
Resistant: C2 – Inclusion Criteria
EGFR T790M
NSCLC
lazertinib
Sensitive: C2 – Inclusion Criteria
EGFR T790M
NSCLC
anlotinib
Sensitive: C2 – Inclusion Criteria
EGFR T790M
NSCLC
AST2818
Sensitive: C2 – Inclusion Criteria
EGFR T790M
NSCLC
STI-5656
Sensitive: C2 – Inclusion Criteria
EGFR T790M
NSCLC
D-0316
Sensitive: C2 – Inclusion Criteria
EGFR T790M
NSCLC
SH-1028
Sensitive: C2 – Inclusion Criteria
EGFR T790M
Lung Non-Squamous Non-Small Cell Cancer
PD-L1 inhibitor
Resistant: C3 – Early Trials
EGFR T790M
NSCLC
EGFR inhibitor
Resistant: C3 – Early Trials
EGFR T790M
LUAD
bevacizumab + osimertinib
Resistant: C3 – Early Trials
EGFR T790M
Lung Cancer
Tyrosine kinase inhibitor
Resistant: C3 – Early Trials
EGFR T790M
NSCLC
Tyrosine kinase inhibitor
Resistant: C3 – Early Trials
EGFR T790M
LUAD
Tyrosine kinase inhibitor
Sensitive: C3 – Early Trials
EGFR T790M
NSCLC
APL-103
Sensitive: C3 – Early Trials
EGFR T790M
NSCLC
WZ4002
Sensitive: C3 – Early Trials
EGFR T790M
NSCLC
erlotinib
Resistant: C3 – Early Trials
EGFR T790M
NSCLC
imatinib
Sensitive: C3 – Early Trials
EGFR T790M
NSCLC
afatinib + ruxolitinib
Sensitive: C3 – Early Trials
EGFR T790M
NSCLC
cetuximab + brigatinib
Sensitive: C3 – Early Trials
EGFR T790M
LUAD
afatinib
Resistant: C3 – Early Trials
EGFR T790M
LUAD
osimertinib + ramucirumab
Sensitive: C3 – Early Trials
EGFR T790M
NSCLC
bevacizumab + erlotinib
Resistant: C3 – Early Trials
EGFR T790M
NSCLC
bevacizumab + gefitinib
Resistant: C3 – Early Trials
EGFR T790M
NSCLC
osimertinib + APG-1252
Sensitive: C3 – Early Trials
EGFR T790M
Gallbladder Cancer
erlotinib
Sensitive: C4 – Case Studies
EGFR T790M
Pancreatic Cancer
erlotinib
Resistant: C4 – Case Studies
EGFR T790M
NSCLC
APG-1252
Sensitive: D – Preclinical
EGFR T790M
NSCLC
osimertinib + DC101
Sensitive: D – Preclinical
EGFR T790M
NSCLC
amivantamab-vmjw
Sensitive: D – Preclinical
EGFR T790M
LUAD
gefitinib + PF-03084014
Sensitive: D – Preclinical
EGFR T790M
NSCLC
MTI-31
Sensitive: D – Preclinical
EGFR T790M
NSCLC
neratinib + PF-05212384
Sensitive: D – Preclinical
EGFR T790M
NSCLC
neratinib
Sensitive: D – Preclinical
EGFR T790M
Lung Cancer
BMS-722782
Sensitive: D – Preclinical
EGFR T790M
Lung Cancer
EGFR inhibitor
Resistant: D – Preclinical